Arcadia Biosciences, Inc. (RKDA) Total liabilities 2017–2025
Arcadia Biosciences, Inc. (RKDA) total liabilities at each fiscal year-end, per SEC filings.
$2.4MFY2025 · since FY2017: $8.6M → $2.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $2.4M | -67.0% |
| FY2024 | $7.3M | +4.2% |
| FY2023 | $7.0M | -12.7% |
| FY2022 | $8.0M | -36.9% |
| FY2021 | $12.7M | -32.3% |
| FY2020 | $18.8M | -22.5% |
| FY2019 | $24.2M | +116.3% |
| FY2018 | $11.2M | +30.9% |
| FY2017 | $8.6M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More RKDA financial trends
RKDA RevenueRKDA Net incomeRKDA Net marginRKDA Gross profitRKDA Gross marginRKDA Operating incomeRKDA Operating marginRKDA Operating cash flowRKDA Free cash flowRKDA Capital expendituresRKDA Return on equityRKDA Stock buybacksRKDA Dividends paidRKDA Total assetsRKDA Shareholders’ equityRKDA overview →